GLIMPSE OF CPHI MILAN ITALY 2024
GLIMPSE OF CPHI SPAIN 2023 :
GLIMPSE OF CPHI THAILAND 2023 :
GLIMPSE OF CPHI CHINA 2023 :
Indian Pharma Manufacturers Roundtable with Bill Gates, Co-Chair – Gates Foundation :
Joint Meeting of Indian Pharma Manufacturers with Bill Gates, Co-Chair – Gates Foundation :
GLIMPSE OF CPHI (1-3 NOVEMBER 2022) FRANKFURT, GERMANY :
MANGALAM DRUGS & ORGANICS LIMITED INKS DEAL WITH EMZOR PHARMACEUTICAL INDUSTRIES LIMITED FOR THE TECHNOLOGY TRANSFER OF FOUR ANTI-MALARIA APIS TO BE MANUFACTURE IN AFRICA.
NEWLY PREQUALIFIED ACTIVE PHARMACEUTICAL INGREDIENTS:
On 28th October 2020, Dolutegravir (sodium) (non-micronised: WHOAPI-386a and micronised: WHOAPI-386b) manufactured by Mangalam Drugs & Organics Ltd has been prequalified by the WHO Prequalification Unit – Medicines Team (PQT/MED) under its API prequalification procedure.
For further details click here.
For further details click here.
OPEN PLEDGE FROM GLOBAL MANUFACTURERS OF GENERIC MEDICINES AGAINST COVID-19:
On 12th November 2020, a united group of 18 companies representing a large portion of the world’s generic pharmaceutical manufacturers against COVID-19 pledged to work together via the Medicines Patent Pool (MPP) to accelerate access to hundreds of millions of doses of new interventions for low- and middle-income countries (LMICs). Mangalam Drugs & Organics Limited is proud to be one of the 18 companies pledging with MPP for the noble cause.
For further details click here.
For further details click here.
CERTIFICATE OF APPRECIATION:
GLIMPSE OFASIA PHARMA EXPO (19-21 MAY 2022) DHAKA, BANGLADESH
GLIMPSE OF CPHI (5-7 NOVEMBER 2019) FRANKFURT, GERMANY
IPHEB RUSSIA | APRIL 2-4, 2019 ST. PETERSBURG:
GLIMPSE OF CPHI (MARCH 12-14 2019), BANGKOK, THAILAND:
GLIMPSE OF IPHEX: NIGERIA, AFRICA
GLIMPSE OF CPHI – 2018 NEW DELHI:
THE STORY BEHIND MANGALAM DRUGS
TARGETTING RS 300 CR REVENUE BY FY17: MANGALAM DRUGS
Speaking to CNBC-TV18 Govardhan Dhoot, MD, Mangalam Drugs, said that margins have improved. Revenue growth is on track and it is looking at Rs 300 crore of revenue by end of FY17. We are Hoping for a 10-15 percent growth, he said. “We are focussing on the topline.”
HOPE TO MAINTAIN RS 80CR QUARTERLY REVENUE RUN RATE: MANGALAM
MIDCAP RADAR: GOVARDHAN DHOOT MD, MANGALAM DRUGS
Mangalam Drugs is the worlds largest manufacturer of anti-malaria APIs, Reema Tendulkar and Mangalam Maloo discuss more about with company and its growth outlook for FY16 with Govardhan Dhoot Managing Director of the company
MANGALAM DRUGS SEES 30-40% GROWTH IN TOPLINE FOR FY12
In an interview with CNBC-TV18, Govardhan Dhoot, MD, Mangalam Drugs Organic, spoke about the latest happenings in his company and the road ahead.
GLIMPSE OF CPHI THAILAND 2023 :
GLIMPSE OF CPHI CHINA 2023 :
Indian Pharma Manufacturers Roundtable with Bill Gates, Co-Chair – Gates Foundation:
Joint Meeting of Indian Pharma Manufacturers with Bill Gates, Co-Chair – Gates Foundation:
GLIMPSE OF CPHI (1-3 NOVEMBER 2022) FRANKFURT, GERMANY:
MANGALAM DRUGS & ORGANICS LIMITED INKS DEAL WITH EMZOR PHARMACEUTICAL INDUSTRIES LIMITED FOR THE TECHNOLOGY TRANSFER OF FOUR ANTI-MALARIA APIS TO BE MANUFACTURE IN AFRICA.
NEWLY PREQUALIFIED ACTIVE PHARMACEUTICAL INGREDIENTS:
On 28th October 2020, Dolutegravir (sodium) (non-micronised: WHOAPI-386a and micronised: WHOAPI-386b) manufactured by Mangalam Drugs & Organics Ltd has been prequalified by the WHO Prequalification Unit – Medicines Team (PQT/MED) under its API prequalification procedure.
For further details click here.
OPEN PLEDGE FROM GLOBAL MANUFACTURERS OF GENERIC MEDICINES AGAINST COVID-19:
On 12th November 2020, a united group of 18 companies representing a large portion of the world’s generic pharmaceutical manufacturers against COVID-19 pledged to work together via the Medicines Patent Pool (MPP) to accelerate access to hundreds of millions of doses of new interventions for low- and middle-income countries (LMICs). Mangalam Drugs & Organics Limited is proud to be one of the 18 companies pledging with MPP for the noble cause.
For further details click here.
CERTIFICATE OF APPRECIATION:
GLIMPSE OFASIA PHARMA EXPO (19-21 MAY 2022) DHAKA, BANGLADESH
GLIMPSE OF CPHI (5-7 NOVEMBER 2019) FRANKFURT, GERMANY
IPHEB RUSSIA | APRIL 2-4, 2019 ST. PETERSBURG:
GLIMPSE OF CPHI (MARCH 12-14 2019), BANGKOK, THAILAND:
GLIMPSE OF IPHEX: NIGERIA, AFRICA
GLIMPSE OF CPHI – 2018 NEW DELHI:
THE STORY BEHIND MANGALAM DRUGS
TARGETTING RS 300 CR REVENUE BY FY17: MANGALAM DRUGS
Speaking to CNBC-TV18 Govardhan Dhoot, MD, Mangalam Drugs, said that margins have improved. Revenue growth is on track and it is looking at Rs 300 crore of revenue by end of FY17. We are Hoping for a 10-15 percent growth, he said. “We are focussing on the topline.”HOPE TO MAINTAIN RS 80CR QUARTERLY REVENUE RUN RATE: MANGALAM
MIDCAP RADAR: GOVARDHAN DHOOT MD, MANGALAM DRUGS
Mangalam Drugs is the worlds largest manufacturer of anti-malaria APIs, Reema Tendulkar and Mangalam Maloo discuss more about with company and its growth outlook for FY16 with Govardhan Dhoot Managing Director of the companyMANGALAM DRUGS SEES 30-40% GROWTH IN TOPLINE FOR FY12
In an interview with CNBC-TV18, Govardhan Dhoot, MD, Mangalam Drugs Organic, spoke about the latest happenings in his company and the road ahead.